company background image
4B70 logo

Antibe Therapeutics DB:4B70 Stock Report

Last Price

€0.19

Market Cap

€10.6m

7D

0%

1Y

-43.0%

Updated

28 May, 2024

Data

Company Financials +

4B70 Stock Overview

A biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. More details

4B70 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Antibe Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Antibe Therapeutics
Historical stock prices
Current Share PriceCA$0.19
52 Week HighCA$0.81
52 Week LowCA$0.10
Beta0.19
1 Month Change0%
3 Month Change-71.73%
1 Year Change-43.03%
3 Year Change-93.19%
5 Year Change-90.69%
Change since IPO-95.00%

Recent News & Updates

Recent updates

Shareholder Returns

4B70DE PharmaceuticalsDE Market
7D0%-2.5%-2.6%
1Y-43.0%-15.6%6.9%

Return vs Industry: 4B70 underperformed the German Pharmaceuticals industry which returned -20.1% over the past year.

Return vs Market: 4B70 underperformed the German Market which returned 8.6% over the past year.

Price Volatility

Is 4B70's price volatile compared to industry and market?
4B70 volatility
4B70 Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 4B70's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 4B70's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200911Dan Legaultwww.antibethera.com

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company’s pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain.

Antibe Therapeutics Inc. Fundamentals Summary

How do Antibe Therapeutics's earnings and revenue compare to its market cap?
4B70 fundamental statistics
Market cap€10.56m
Earnings (TTM)-€12.32m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4B70 income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$18.24m
Earnings-CA$18.24m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.34
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 4B70 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/28 01:09
End of Day Share Price 2024/04/10 00:00
Earnings2023/12/31
Annual Earnings2023/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Antibe Therapeutics Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sally YanchusBrookline Capital Markets
Tania Armstrong-WhitworthCanaccord Genuity
Robert GoffEchelon Wealth Partners Inc.